LLY

753.06

+1.44%↑

UNH

519.23

-1%↓

JNJ

145.22

-1.89%↓

ABBV

169.25

-1.82%↓

NVO

80.63

-0.42%↓

LLY

753.06

+1.44%↑

UNH

519.23

-1%↓

JNJ

145.22

-1.89%↓

ABBV

169.25

-1.82%↓

NVO

80.63

-0.42%↓

LLY

753.06

+1.44%↑

UNH

519.23

-1%↓

JNJ

145.22

-1.89%↓

ABBV

169.25

-1.82%↓

NVO

80.63

-0.42%↓

LLY

753.06

+1.44%↑

UNH

519.23

-1%↓

JNJ

145.22

-1.89%↓

ABBV

169.25

-1.82%↓

NVO

80.63

-0.42%↓

LLY

753.06

+1.44%↑

UNH

519.23

-1%↓

JNJ

145.22

-1.89%↓

ABBV

169.25

-1.82%↓

NVO

80.63

-0.42%↓

Search

BioMarin Pharmaceutical Inc

Closed

Sector Healthcare

62 -0.96

Overview

Share price change

24h

Current

Min

61.58

Max

62.57

Key metrics

By Trading Economics

Income

-1.1M

106M

Sales

34M

746M

P/E

Sector Avg

39.533

59.526

EPS

0.91

Profit margin

14.22

EBITDA

-29M

133M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+55.13 upside

Dividends

By Dow Jones

Next Earnings

20 Feb 2025

Market Stats

By TradingEconomics

Market Cap

-666M

12B

Previous open

62.96

Previous close

62

News Sentiment

By Acuity

25%

75%

50 / 392 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

BioMarin Pharmaceutical Inc Chart

Past performance is not a reliable indicator of future results.

Related News

10 Jun 2024, 17:41 UTC

Major Market Movers

Texas Pacific Land, Altair Engineering Hit 52-Week Highs on S&P MidCap 400 Inclusion

21 Aug 2024, 11:30 UTC

Top News

S&P 500 Futures Up In Premarket Trading; Target, Keysight Technologies Lead

Peer Comparison

Price change

BioMarin Pharmaceutical Inc Forecast

Price Target

By TipRanks

55.13% upside

12 Months Forecast

Average 97 USD  55.13%

High 127 USD

Low 65 USD

Based on 25 Wall Street analysts offering 12 month price targets forBioMarin Pharmaceutical Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

25 ratings

18

Buy

7

Hold

0

Sell

Technical Score

By Trading Central

61.38 / 67.425Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Weak Bearish Evidence

Long Term

Weak Bearish Evidence

Sentiment

By Acuity

50 / 392 Healthcare

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About BioMarin Pharmaceutical Inc

BioMarin Pharmaceutical Inc. is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company's therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A). The Company is conducting clinical trials on various product candidates for the treatment of various diseases. Its clinical product candidates include Brineura, pegvaliase, vosoritide, BMN 270 and BMN 250.